Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Establishing a National SABR Service: A Model for Safe and Effective Clinical Implementation.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025

Same author

Hypogammaglobulinemia and infection rates in patients with multiple sclerosis treated with ocrelizumab for up to six years: A real-world single-center study.

Multiple sclerosis journal - experimental, translational and clinical·2025

Same author

Xylem morphology influences lemon susceptibility to mal secco disease.

Plant biology (Stuttgart, Germany)·2025

Same author

First Constraint on Atmospheric Millicharged Particles with the LUX-ZEPLIN Experiment.

Physical review letters·2025

Same author

New Constraints on Cosmic Ray-Boosted Dark Matter from the LUX-ZEPLIN Experiment.

Physical review letters·2025

Same author

Dark Matter Search Results from 4.2 Tonne-Years of Exposure of the LUX-ZEPLIN (LZ) Experiment.

Physical review letters·2025

Search research articles

Related Experiment Video

Updated: May 9, 2026

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Stereotactic ablative radiotherapy in the UK: current status and developments.

P Jain¹, A Baker, G Distefano

¹Department of Oncology, Clatterbridge Cancer Centre, Bebington, UK. pjain@nhs.net

The British Journal of Radiology

|July 23, 2013

Summary

Stereotactic ablative radiotherapy (SABR) is now established for treating early lung cancer in medically inoperable patients. The UK SABR Consortium guides implementation, with over 30 centers expected to offer SABR by end of 2014.

More Related Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Related Experiment Videos

Last Updated: May 9, 2026

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Area of Science:

Oncology
Radiotherapy
Medical Physics

Background:

Stereotactic ablative radiotherapy (SABR) evolved from stereotactic radiosurgery for brain metastases.
Advances in technology and evidence have established SABR for medically inoperable early lung cancer.
Multidisciplinary team collaboration is essential for safe SABR delivery.

Purpose of the Study:

To describe the implementation and development of extracranial SABR across the UK.
To outline the role of the UK SABR Consortium in standardizing SABR practices.
To highlight the progress and future directions of SABR in the UK.

Main Methods:

Development of collective guidance for patient selection, planning, and delivery techniques.
Establishment of the UK SABR Consortium to coordinate centers and share expertise.
Implementation of a mentoring program to support new SABR centers.

Main Results:

At least 15 UK centers are currently delivering SABR, with over 500 patients treated under Consortium guidance.
Over 30 UK centers are anticipated to offer SABR by the end of 2014.
Consistent UK guidance facilitates toxicity and outcome auditing, contributing to international SABR experience.

Conclusions:

SABR is an established treatment for early lung cancer in the UK.
The UK SABR Consortium plays a vital role in standardizing and promoting SABR.
Future priorities include further clinical research and participation in international trials.